For heart failure, digoxin levels are usually targeted around 0.5–0.9 ng/mL; for atrial fibrillation, current US guidance recommends below 1.2 ng/mL when levels are measured. Samples generally need at least 6–8 hours after a dose. Toxicity can occur within the laboratory interval, especially with kidney impairment, low potassium or magnesium, or interacting medicines.
- Digoxin therapeutic range depends on the indication: heart-failure guidance specifies 0.5 to less than 0.9 ng/mL, while atrial-fibrillation guidance recommends below 1.2 ng/mL when monitoring is indicated.
- Sample timing generally requires at least 6–8 hours after the last dose; a sample immediately before the next dose is often easiest to interpret.
- Steady state usually takes approximately 7–10 days with normal kidney function and can take substantially longer with kidney impairment.
- Cunnart puinnseanta increases above 2 ng/mL, but a lower result does not exclude clinically significant toxicity.
- Obair dubhag determines much of digoxin clearance; dehydration or acute kidney injury can make an unchanged prescription unsafe.
- Electrolytes matter independently: potassium below 3.5 mmol/L and low magnesium increase susceptibility to digoxin-related arrhythmias.
- Eadar-obrachadh include amiodarone, verapamil and certain antibiotics; some medicines also slow the heart without raising the measured digoxin concentration.
- Comharraidhean èiginneach include fainting, new confusion, persistent vomiting, visual changes or a slow or irregular heartbeat, particularly when several occur together.
- Aonadan are interchangeable only with conversion: 1 ng/mL equals 1 µg/L and approximately 1.28 nmol/L.
What digoxin level should your clinician target?
A digoxin level has no single universally safe target. Heart failure generally calls for a lower concentration than older laboratory intervals suggest, while atrial-fibrillation treatment also depends on heart rate, symptoms and other medicines—not simply whether the result falls inside a printed range.
The 2022 AHA/ACC/HFSA heart-failure guideline lists a serum digoxin target of 0.5 to less than 0.9 ng/mL, whereas the 2023 US atrial-fibrillation guideline recommends below 1.2 ng/mL when a concentration is measured (Heidenreich et al., 2022; Joglar et al., 2024). These are treatment targets, not guarantees that every patient within them is safe.
A laboratory may still print 0.8–2.0 ng/mL, depending on its assay and reporting policy; that interval should not override an indication-specific prescription plan. Conversely, a heart-failure result of 0.6 ng/mL may be appropriate even if a laboratory flags it as low—the flag reflects the laboratory's chosen interval, not necessarily inadequate treatment.
Tha Kantesti na Anailisiche deuchainn fala AI that can help organize a digoxin result alongside kidney and electrolyte measurements, but the prescriber determines the treatment target. I'm Thomas Klein, MD, Chief Medical Officer; my first question about a result such as 1.1 ng/mL is why digoxin was prescribed, and our buidheann agus misean clionaigeach explain that distinction between interpretation support and prescribing.
Why heart failure usually needs a lower digoxin level
Lower digoxin concentrations are preferred in heart failure because additional exposure can add risk without a proven survival benefit. Digoxin may reduce heart-failure hospitalizations in selected patients with persistent symptoms despite appropriate treatment, but it is not a substitute for the medicines that improve survival.
An 2022 heart-failure guideline gives digoxin a selective role in symptomatic heart failure with reduced ejection fraction despite guideline-directed treatment, or when that treatment cannot be tolerated (Heidenreich et al., 2022). Its discussion reflects evidence that hospitalization benefit and concentration-related risk must be balanced; raising a result from 0.7 to 1.4 ng/mL is not an automatic improvement.
A concentration of 0.5 ng/mL does not tell you whether congestion is controlled, blood pressure is adequate or the underlying treatment plan is complete. Symptoms, weight trends, examination findings and other cardiac measurements answer different questions; our guide to NT-proBNP and heart-failure symptoms explains why a heart-failure marker is not interchangeable with a medication concentration.
Consider a hypothetical Boireannach 78-bliadhna whose breathlessness worsens while the digoxin level remains 0.7 ng/mL: the useful next step is assessing fluid status, kidney function, adherence and the rest of the regimen, not simply increasing digoxin. If that same person develops nausea and bradycardia, the apparently reassuring concentration should not prevent an assessment for toxicity.
How atrial fibrillation changes the digoxin therapeutic range
For atrial fibrillation, digoxin monitoring supports a rate-control plan rather than defining one. The 2023 ACC/AHA/ACCP/HRS guideline recommends targeting a concentration below 1.2 ng/mL when levels are measured, with lower exposure often appropriate in patients who also have heart failure or increased toxicity risk.
An below-1.2 ng/mL recommendation is an upper target, not a requirement to reach 1.1 ng/mL or a reason to reject a lower concentration that achieves the clinical goal (Joglar et al., 2024). Digoxin primarily slows conduction through the atrioventricular node; it does not reliably restore sinus rhythm, and it does not replace a separate assessment of stroke-prevention treatment.
Resting heart rate and exertional heart rate can tell different stories because digoxin's rate-control effect is less reliable during increased sympathetic activity. A patient with a resting pulse of 76 beats/minute may still have troublesome exertional tachycardia, so the clinician may assess activity-related symptoms or ambulatory recordings; our palpitations assessment guide describes the complementary role of laboratory tests.
There is no sensible universal dose escalation for an atrial-fibrillation level of 0.4 ng/mL without knowing the clinical response. If the patient also takes a beta-blocker and has dizziness with a pulse of 48 beats/minute, increasing digoxin could make matters worse even though the concentration looks low; combined effects on conduction matter more than the isolated number.
Why samples wait at least 6–8 hours after a dose
Digoxin samples are generally collected at least 6–8 hours after a dose because the medicine first distributes from the circulation into tissues. A sample obtained during that distribution phase can overstate the concentration used to assess maintenance treatment and may prompt an unnecessary dose change.
An 6–8-hour interval addresses distribution, not whether breakfast was eaten or whether the laboratory is busy. A digoxin result collected 2 uair after an oral dose cannot usually be compared directly with a stable, pre-dose result; the consensus review by Andrews and colleagues emphasizes waiting at least , geir visceral a dh’aindeoin BMI àbhaisteach, tinneas an t-siùcair gestational roimhe, agus eachdraidh làidir teaghlaich uile glucose a thogail às dèidh biadh fada mus, ideally longer, for concentration interpretation after ingestion (Andrews et al., 2023).
An early high result is not automatically proof of toxicity, but it is not automatically harmless either. If a patient feels well and the dose history is reliable, the clinician may request a correctly timed repeat; if there is fainting, significant bradycardia or suspected overdose, assessment proceeds immediately rather than waiting 8 uairean to make the result easier to interpret.
Distribution timing is distinct from a strict trough requirement, which is why medication-specific instructions matter. Our explanation of carbamazepine trough timing offers a useful comparison, but do not transfer another drug's sampling schedule to digoxin; record the actual dose time and collection time, ideally to the nearest hour.
How to schedule a useful digoxin blood test
A pre-dose sample is often the simplest way to obtain an interpretable digoxin level. The essential details are the time of the last dose, the time of collection and the prescribed schedule; follow the laboratory or prescriber's instructions rather than independently skipping treatment.
For a person taking digoxin every morning at 8 a.m., collection just before the next morning's dose is approximately 24 uairean after the previous dose. A draw at 10m. after taking the usual morning tablet is only 2 uair later and usually unsuitable for routine maintenance interpretation; confirm in advance whether the morning dose should be taken after collection.
Evening dosing creates a different practical option: a dose at 8 p.m. followed by a sample at 8 a.m. a’ toirt seachad 12-hour interval and is generally beyond the distribution phase. However, results from 12-hour agus 24-hour samples are not perfectly interchangeable, so use a consistent interval for trends whenever possible rather than treating every small difference as a physiological change.
Fasting is not ordinarily required for digoxin alone, although another ordered test may require it. Bring a record of any missed, delayed or extra doses over the preceding week; unlike the more specific conventions discussed in tacrolimus trough monitoring, the request for a digoxin level should explicitly state the intended sampling interval.
When to check digoxin levels—and when not to
Check digoxin levels when toxicity is suspected, kidney function changes, interacting medicines change, adherence is uncertain or a dose adjustment needs assessment. Stable patients do not necessarily need frequent routine concentrations; after a maintenance-dose change, an elective check usually waits until the new concentration approaches steady state.
Digoxin's elimination half-life is approximately 36–48 hours in people with normal kidney function, so a maintenance concentration commonly approaches steady state after about 7–10 làithean. Kidney impairment can extend that interval substantially; a level taken 2 latha after a dose reduction may still largely reflect the old regimen, although it can still contribute to an urgent safety assessment.
Routine monitoring should also include kidney function, potassium and magnesium, often at least gach bliadhna in otherwise stable patients and more frequently when age, illness or other treatment increases risk. A new diuretic, vomiting illness or change in renal function can justify earlier testing; our stiùireadh gluasad sàbhailteachd cungaidh-leigheis explains why the event triggering a test matters as much as the calendar.
Tha Kantesti na àrd-ùrlar mìneachaidh deuchainn fala AI that can help compare a current digoxin result with related laboratory trends when those results and the dosing history are supplied. A change from 0.6 to 1.0 ng/mL deserves a check of sample timing and kidney function before it is described as accumulation; symptoms, however, can make that review urgent rather than elective.
How kidney function can turn a stable dose unsafe
Reduced kidney clearance can raise digoxin exposure without any change in the prescribed dose. Acute kidney injury, dehydration and chronic kidney disease therefore change the meaning of a previously acceptable level; older adults with low muscle mass may have more renal impairment than their creatinine concentration suggests.
A creatinine increase from 0.9 gu 1.3 mg/dL—approximately 80 to 115 µmol/L—may be clinically meaningful, especially when it occurs quickly in a small older adult. The immediate issue is the change in clearance, not whether the latest creatinine barely crosses the laboratory boundary; our low-eGFR warning signs help distinguish a laboratory trend from an illness needing prompt assessment.
Estimated GFR is less reliable during rapidly changing kidney function because creatinine has not reached equilibrium, so yesterday's calculated value may lag behind today's illness. A 3-day episode of vomiting can reduce kidney clearance and disturb electrolytes at the same time; our dehydration and GFR guide explains why a temporary trigger can still create a serious medication-safety problem.
Digoxin dosing may require a drug-dosing estimate such as creatinine clearance rather than simply copying the laboratory's body-surface-area-indexed eGFR, particularly at body-size extremes. A BUN/creatinine ratio above 20:1, when both are expressed in mg/dL, can support certain clinical hypotheses but cannot set a digoxin dose; our BUN/creatinine interpretation guide explains its limitations.
Why potassium, magnesium and calcium change toxicity risk
Low potassium and low magnesium increase susceptibility to digoxin-related arrhythmias, even when the measured digoxin level is within the laboratory interval. High calcium can also increase risk; in a substantial acute overdose, high potassium may instead reflect severe sodium–potassium pump inhibition.
Potasium fo 3.5 mmol/L is generally considered low, and low extracellular potassium increases digoxin's effect at the sodium–potassium ATPase pump. A patient taking a loop diuretic may therefore develop rhythm problems at 0.8 ng/mL if potassium has fallen to 2.9 mmol/L; tha an electrolyte-panel assessment guide explains why these results should be interpreted together.
Magnesium below approximately 0.7 mmol/L, depending on the laboratory, can promote arrhythmias and make potassium correction more difficult. Diuretics, gastrointestinal losses and long-term proton-pump inhibitor use can contribute; our low-magnesium causes guide explains why a normal potassium result does not make magnesium irrelevant, and why replacing either electrolyte should follow a clinician's plan.
High potassium in suspected acute digoxin poisoning is a different warning from low potassium during chronic treatment; 6.5 mmol/L or more is a severe abnormality, but lower values can still require urgent action in context. A hemolyzed sample can falsely elevate potassium, as discussed in mearachdan cruinneachaidh potasium, yet suspected poisoning must not be dismissed while arranging confirmation.
Which medicines can raise digoxin levels or cardiac risk?
Amiodarone, verapamil, quinidine and certain antibiotics can increase digoxin exposure, while other medicines add cardiac effects without necessarily raising the level. The interaction review should include prescriptions, over-the-counter products and supplements, with particular attention to new drugs started during an acute illness.
Amiodarone inhibits pathways involved in digoxin transport and clearance; a prescriber commonly reduces an existing digoxin dose by around 50% when amiodarone is started, with individualized monitoring. That is a clinical prescribing consideration, not a home-adjustment instruction; the interaction can evolve over time, and a single reassuring concentration shortly after the change does not establish long-term safety.
Clarithromycin and erythromycin can increase digoxin exposure through transport effects and, in some patients, changes in intestinal handling of the drug. A hypothetical 75-year-old who develops nausea several days after starting an antibiotic needs the interaction and kidney function reviewed, not just treatment for indigestion; our older-adult medication-effects guide shows why new symptoms deserve a complete medication reconciliation.
Beta-blockers, diltiazem and verapamil may add to atrioventricular conduction slowing, so a pulse of 45 beats/minute can be concerning despite an unremarkable digoxin result. Loop or thiazide diuretics create a different route to risk by lowering potassium or magnesium; spironolactone and its metabolites can also affect some digoxin assays, making the laboratory method relevant when a result seems inconsistent.
Which digoxin toxicity symptoms need urgent assessment?
Possible digoxin toxicity symptoms include nausea, vomiting, loss of appetite, unusual weakness, confusion, visual changes and a slow or irregular heartbeat. Fainting, chest pain, severe breathlessness, marked confusion or palpitations with dizziness require emergency assessment; do not wait for a repeat digoxin level.
New persistent vomiting, reduced appetite or unexplained confusion during digoxin treatment warrants prompt, often same-day, clinical advice—especially with recent dehydration or medication changes. A level of 0.9 ng/mL cannot rule out toxicity in that setting, and yellow-green vision or halos are possible but not required; many patients present without the visual symptoms commonly associated with the drug.
A very slow pulse, for example below 50 beats/minute, becomes particularly concerning when accompanied by dizziness, weakness or fainting; the patient's baseline and other medicines still matter. Chest pain or severe breathlessness should trigger emergency evaluation regardless of the last digoxin result, and our urgent chest-pain assessment guide explains why laboratory interpretation cannot replace immediate cardiac assessment.
If overdose is possible, contact emergency services or a poison-information service immediately, even if symptoms have not started within the first hour. When toxicity is suspected, seek advice urgently before the next dose; the assessing team will usually withhold digoxin while evaluating the situation, but patients should not make a permanent treatment change or take an extra dose to compensate.
What can make a digoxin result misleading?
An unexpected digoxin level can reflect early sampling, a reporting error, assay interference or a genuinely unsafe concentration. After digoxin-specific antibody treatment, routine total-digoxin measurements may become especially misleading because many assays detect antibody-bound drug as well as unbound drug.
First verify the units: Tha 1 ng/mL co-ionann ri 1 µg/L, agus 1 ng/mL is approximately 1.28 nmol/L. Toradh de 1.3 nmol/L is therefore about 1.0 ng/mL, chan e 1.3 ng/mL; transcription mistakes and missing collection times are avoidable sources of confusion, and our liosta-sgrùdaidh airson mearachdan às-tharraing PDF helps readers check imported laboratory data.
Digoxin-like immunoreactive substances can interfere with some assays, including in certain patients with kidney or liver dysfunction, and interference is method-dependent rather than universal. If a result rises from 0.7 to 1.6 ng/mL without a plausible dosing, timing or clinical explanation, the clinician can ask the laboratory about its method and potential cross-reactivity instead of assuming the patient took extra tablets.
Digoxin immune Fab is used for potentially life-threatening toxicity, including serious arrhythmias, severe conduction disturbance or significant hyperkalemia in the appropriate setting (Andrews et al., 2023). After treatment, total concentrations may appear high for days or longer and should not guide routine redosing; clinical status, ECG and electrolytes take priority, while dialysis generally removes digoxin poorly because much of the drug is distributed in tissues.
Does a low or high result mean your dose must change?
A digoxin dose should not be changed solely because a laboratory marks the level low or high. The prescriber needs the indication, symptoms, sample timing, recent dose history, kidney function and electrolytes; an elevated correctly timed result without symptoms still deserves prompt clinical review.
Common maintenance prescriptions use small doses such as 62.5, 125 or 250 micrograms, but the appropriate regimen depends on renal function, lean body size and clinical need. The unit conversion matters: 125 micrograms equals 0.125 mg, chan e 1.25 mg; confirm tablet strength and dispensing instructions whenever the packaging changes, and never estimate a replacement dose from the concentration alone.
A low result can reflect missed doses, a lower prescribed target, a long interval since the last dose or reduced absorption, so 0.4 ng/mL is not a diagnosis of treatment failure. The same general need for drug-specific interpretation appears in lithium kidney monitoring, but lithium's targets and dose-adjustment rules must never be applied to digoxin.
For an asymptomatic, correctly timed result of 2.3 ng/mL, contact the prescribing team promptly, preferably the same day, rather than waiting for a routine visit; any concerning symptoms move the situation into urgent assessment. A missed dose should be handled according to the prescription leaflet or pharmacist's advice, and 2 doses should not be taken together simply to catch up.
How to prepare a safe digoxin follow-up review
A useful follow-up review combines the digoxin concentration with symptoms, dose timing, kidney results, electrolytes and a complete medication list. Tha Kantesti na Inneal mion-sgrùdaidh deuchainn fala le cumhachd AI that can help organize supplied laboratory information, but it cannot examine you, obtain an ECG or authorize a prescription change.
Ullaich 6 pieces of information: the dose and tablet strength, treatment indication, last-dose time, collection time, current symptoms and recent medication changes. Include creatinine or eGFR, potassium and magnesium from the relevant date rather than an unrelated older panel; our mìneachadh teicneòlas AI describes why supplied context and source quality shape the usefulness of an interpretation.
Kantesti's interpretation support should never turn a concentration such as 0.8 ng/mL into an unconditional reassurance when the patient is fainting or vomiting. As Thomas Klein, MD, I would rather see an incomplete report accompanied by an accurate symptom history than a polished report missing the dose time; our frèam dearbhaidh clionaigeach should be read as methodology information, not proof that software can exclude an acute arrhythmia.
Privacy also belongs in the follow-up workflow: share only the records needed for the clinical question and obtain permission before uploading another person's results. Kantesti supports laboratory trend review, but an AI response in approximately 60 diog is not emergency triage; our liosta-sgrùdaidh prìobhaideachd airson luchdachadh thoraidhean explains practical checks before sharing a PDF or photograph.
Research publications and the evidence behind this advice
The digoxin targets in this article come from cardiac guidelines, while sampling and toxicity advice also draw on a clinical consensus review. Mar 8 Dàmhair, 2026, the sources cited here are the 2022 heart-failure guideline, the 2023 atrial-fibrillation guideline published in 2024, and the 2023 digoxin-toxicity consensus—not an invented 2026 recommendation.
An 2 Zenodo publications listed below provide background on laboratory interpretation, not primary evidence for digoxin targets or antidote decisions. Their formal citations use the supplied publication titles with the organization as corporate author and no assumed publication date; ResearchGate and Academia.edu links are clearly identified as title searches, because a specific hosted copy has not been established.
Kantesti LTD. (n.d.). RDW blood test: Complete guide to RDW-CV, MCV & MCHC. Zenodo. This publication addresses red-cell indices rather than therapeutic drug monitoring; a reader comparing RDW-CV percentages with a digoxin value in ng/mL can use the RDW background publication to understand why unrelated markers cannot establish medication safety.
Kantesti LTD. (n.d.). BUN/creatinine ratio explained: Kidney function test guide. Zenodo. This background resource supports renal-context discussion but cannot translate a ratio above 20:1 into a digoxin prescription; Kantesti's fiosrachadh comhairleachaidh meidigeach describes the clinical expertise behind our educational approach, while urgent symptoms still require direct medical assessment.
Ceistean Bitheanta
Dè an raon teirpeach airson ìre digoxin?
Tha raon leigheasach an digoxin an urra ris an comharra làimhseachaidh an àite aon ùine obair-lann uile-choitcheann. Tha stiùireadh cridhe-fàilligeadh na SA 2022 a' sònrachadh 0.5 gu nas lugha na 0.9 ng/mL, fhad 's a tha stiùireadh clisgeadh atrial na SA 2023 a' moladh fo 1.2 ng/mL nuair a thèid dùmhlachdan a thomhas. Tha cuid de obair-lannan fhathast ag aithris amannan leithid 0.8–2.0 ng/mL, ach cha bu chòir dhaibh seo a bhith nas fheàrr na targaid sònraichte an dotair òrdaichidh. Tha comharran, gnìomh dubhaig, electrolytes agus àm an sampall fhathast riatanach airson mìneachadh.
Cuin a bu chòir tomhas digoxin a ghabhail an dèidh dòs?
Mar as trice bithear a' cruinneachadh ìre digoxin co-dhiù 6–8 uairean an dèidh na dòis mu dheireadh gus nach dèan cuairteachadh tràth anns na nèapraigean an toradh mì-chreidsinneach. Bidh sampall dìreach ron ath-shuidheachadh clàraichte gu tric goireasach agus nas fhasa a choimeas thar ùine. Airson làimhseachadh aon uair san latha, mar as trice bidh an sampall ro-dòis sin timcheall air 24 uairean an dèidh na dòis roimhe. Tha amharas air puinnseanachadh ag iarraidh measadh sa bhad an àite a bhith a' cur dàil air cùram gus sampall air leth freagarrach fhaighinn.
An urrainn do phuinnseanachadh digoxin tachairt le ìre dhigoxin àbhaisteach?
Faodaidh puinnseanachd digoxin tachairt taobh a-staigh raon-ama obair-lann, a’ gabhail a-steach aig dùmhlachdan fo 2 ng/mL. Faodaidh potassium ìosal, magnesium ìosal, dìth dubhaig agus cungaidhean eadar-ghnìomhach barrachd buaireadh a dhèanamh no buaidhean cridhe a chur ris. Chan eil toradh 0.8 ng/mL a’ dùnadh a-mach puinnseanachd ann an cuideigin le cuir a-mach, troimh-chèile, lagachadh no buille cridhe mall no neo-riaghailteach. Tha feum air measadh clionaigeach, ECG agus deuchainnean obair-lann co-cheangailte nuair a tha amharas ann mu phuinnseanachd.
Dè cho fada an dèidh atharrachadh dòis a bu chòir sùil a chumail air ìrean digoxin?
An dèidh atharrachadh ann an dòs cumail suas, mar as trice bidh ìre digoxin roghnach a' feitheamh mu 7–10 latha ann an neach le gnìomh dubhaig àbhaisteach. Tha leth-beatha às-thoirmeasg àbhaisteach digoxin timcheall air 36–48 uairean, agus tha feum air grunn leth-bheathaichean gus an ùr-stad a ruighinn. Faodaidh mì-ghnìomh dubhaig an ùine feithimh seo a leudachadh gu mòr. Tha comharran ùra no teagamh mu puinnseanta a' fìreanachadh measadh agus deuchainn nas tràithe seach a bhith a' feitheamh ris an stàit stèidhichte.
Dè tha air sgàth puinnseantaidheachd digoxin feumach air cuideachadh èiginn?
Fiosrachadh mu fhannachadh, pian anns a' chiste, anail gann, troimh-chèile mòr no prìnean le ceann-troimh-chèile rè làimhseachadh le digoxin a' feumachdainn measadh èiginn. Tha cuisle fo 50 buillean/mionaid gu sònraichte draghail nuair a tha e air a dhol còmhla ri laigse, ceann-troimh-chèile no faoin-inntinn, ged a tha bun-loidhne an euslaintich cudromach. Tha cuir a-mach leantainneach, atharrachaidhean lèirsinneach ùr no dìth càil airidh air comhairle clionaigeach luath, gu h-àraidh an dèidh dìth uisge no atharrachadh cungaidh-leigheis. Na bi a' feitheamh ri ìre digoxin ath-aithris ma tha comharran dona no overdose comasach an làthair.
A bheil ìre àrd de dhioxyin a' ciallachadh gum bu chòir dhomh stad a ghabhail air?
A high digoxin level requires prompt advice from the prescribing team, but the result alone should not lead to an unsupervised permanent treatment change. An asymptomatic, correctly timed concentration above 2 ng/mL deserves prompt review of the dose, kidney function, electrolytes and interactions. If toxicity symptoms are present, seek urgent assessment before the next dose; the clinical team will usually withhold digoxin while evaluating the situation. An early sample taken only 2 hours after a dose may need a correctly timed repeat, but serious symptoms must not be dismissed as a timing issue.
Faigh Mion-sgrùdadh Deuchainn Fala le Cumhachd AI an-diugh
Thig còmhla ri còrr is 2 mhillean neach air feadh an t-saoghail a tha a’ earbsa Kantesti airson mion-sgrùdadh sa bhad, ceart air deuchainnean obair-lann. Luchdaich suas na toraidhean deuchainn fala agad agus faigh mìneachadh coileanta air biomarcair 15,000+ ann an diogan.
📚 Foillseachaidhean Rannsachaidh le Iomraidhean
Klein, T., Mitchell, S., & Weber, H. (2026). Deuchainn fala RDW: Iùl coileanta air RDW-CV, MCV & MCHC. Rannsachadh Leigheis AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). Mìneachadh air Co-mheas BUN/Creatinine: Stiùireadh airson Deuchainn Gnìomh nan Dubhagan. Rannsachadh Leigheis AI Kantesti.
📖 Iomraidhean Meidigeach Taobh a-muigh
Heidenreich PA et al. (2022). Stiùireadh 2022 AHA/ACC/HFSA airson Riaghladh Fàilligeadh Cridhe. Circulation.
Joglar JA et al. (2024). Stiùireadh 2023 ACC/AHA/ACCP/HRS airson breithneachadh agus riaghladh fibrillation atrial. Circulation.
Andrews P et al. (2023). Diagnosis and practical management of digoxin toxicity: a narrative review and consensus. European Journal of Emergency Medicine.
⚕️ Àicheadh Meidigeach
Tha an artaigil seo dìreach airson adhbharan foghlaim agus chan eil e a’ dèanamh comhairle mheidigeach. Cuir fios an-còmhnaidh gu solaraiche cùram slàinte teisteanasach airson co-dhùnaidhean breithneachaidh is leigheis.
Comharran earbsa E-E-A-T
Eòlas
Lèirmheas clionaigeach air a stiùireadh le lighiche air sruthan-obrach mìneachaidh obair-lann.
Eòlas
Fòcas air leigheas obair-lann air mar a bhios bith-chomharraidhean (biomarkers) a’ giùlan ann an co-theacsa clionaigeach.
Ùghdarrasachd
Air a sgrìobhadh le Dr. Thomas Klein le ath-sgrùdadh le Dr. Sarah Mitchell agus Prof. Dr. Hans Weber.
Earbsachd
Mìneachadh stèidhichte air fianais le slighean leanmhainn soilleir gus dragh a lughdachadh.